Boehringer Ingelheim Chemicals, Inc. Announces Closure of Original Production Facility

Contact: Jaime Belitz
Manager, Communications & PR
Boehringer Ingelheim Chemicals, Inc.
804-504-8468
[email protected]

Boehringer Ingelheim Chemicals, Inc. Announces Closure of Original Production Facility

Petersburg, VA – September 14, 2012 - Over the past several years, we have been evaluating the future of our original production facility, Synthesis 1 (S1), and whether it was a good business decision to keep open due to the age of the facility and the future capacity needs of the Corporation.

It is now clear that it is not feasible or necessary to keep S1 in operation. Therefore, over the next months, we will be evaluating and planning for the shutdown of this facility mid-year 2013. There are many details involved with this closure including evaluating production commitments, decommissioning equipment, evaluating resource requirements, etc. At this time, we do not have all the details or plans in place but it is estimated that 80-100 people will be affected.

It is important to emphasize that our other two production facilities, Synthesis 3 and Synthesis 5, will remain open and active. We are dedicated to delivering on our commitments as we manufacture life-saving medications for patients. Our mission remains the same: to improve and save lives.

We recognize this change greatly impacts our employees, their families and the community. We have always been committed to taking care of our employees…we are committed to doing the same in this difficult situation. We will work to keep our employees informed as we finalize details and next steps.

Boehringer Ingelheim Chemicals, Inc. is a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies.

Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.